5002412026-05-142026-05-145002412026-05-145002412026-05-14ChangeInManagementDomain15002412026-05-142026-05-14ChangeInManagementDomain15002412026-05-14ChangeInManagementDomain25002412026-05-142026-05-14ChangeInManagementDomain25002412026-05-14ChangeInManagementDomain35002412026-05-142026-05-14ChangeInManagementDomain3xbrli:pureKIRLOSBROSKIRLOSKAR BROTHERS LIMITED500241NOTLISTEDINE732A01036trueListed Entity (self)true2026-05-1309:30:0013:30:0032026-05-14AppointmentDirectorExecutive DirectorNot ApplicableMDMs.Rama Sanjay Kirloskar2026-08-0360Ms. Rama Kirloskar (DIN 07474724), age 36, is a Director on the Board of the Company, from July 28, July 2017 and has been appointed as a Joint Managing Director of the Company, from August 03, 2021. She also serves as Managing Director of Kirloskar Ebara Pumps Limited (KEPL). KEPL is a joint venture between Ebara Corporation, Japan and Kirloskar Brothers Limited, parent company of the 130-year-old Kirloskar Group. She has been instrumental in the turnaround of KEPL into a debt free company. Previously, she was General Manager and Head of the Product Portfolio Management at Kirloskar Brothers Limited, where she was responsible for driving the Go-to-market strategy, product value management and restructuring for the mass production business; material grade rationalization and streamlining for the foundry business and product rationalization for the made-to-order business. She holds a double major in Mathematics and Biology from Bryn Mawr College, USA. After graduation, she went on to work at Polaris Partners, a multi-stage venture capital firm that principally invests in technology, healthcare and consumer products, headquartered at Boston, MA, USA. Subsequently, she worked at the Koch Institute at Massachusetts Institute of Technology (MIT), USA. Her research led her and the team to begin working with Visterra Inc., an MIT biotechnology start-up company that currently uses its proprietary platform to design therapeutics for infectious diseases. She is one of the authors of a publication in the journal Cell (Robinson et al.,2015, Cell 162,1–12, doi:10.1016/j.cell.2015.06.057), in the paper titled “Structure-Guided Design of an Anti-Dengue Antibody Directed to a Non-Immunodominant Epitope”. Ms. Rama Kirloskar has diverse experience in the areas of strategy, information technology and executive management. She is also on the Board of Karad Projects and Motors Limited and Prakar Investments Private Limited. She also holds directorship in other listed entities, namely, KPT Industries Limited and DCM Shriram Fine Chemicals Limited as an Independent Director. She is on the Executive Council of AGNIi (Accelerating Growth of New India’s Innovations), a programme of the Office of the Principal Scientific Adviser to the Government of India and a Mission under the Prime Minister’s Science Technology and Innovation Advisory Council (PM-STIAC).Sanjay Kirloskar - Chairman & Managing Director (Father) and Alok Kirloskar, Non-executive director (Brother)truefalseAppointmentAuditorsInternal AuditorM/s.PricewaterhouseCoopers Private Limited2026-05-1312PwC is a global consulting firm with substantial operations in India and specialization in Governance, Risk & Compliance (GRC) services.AppointmentAuditorsCost AuditorsM/s.Harshad S Deshpande & Associates2026-05-1312M/s. Harshad S. Deshpande & Associates, Cost Accountants, are a new age leading firm of cost accountants and in practice for more than 20 years. They offer professional services in the field of Cost & Management accounting, Banking & Finance, Insolvency Laws, Forensic Audit, Valuations, Indirect Tax and Social Audit.